[Oral trapidil treatment of Fontaine stage II arteriosclerotic circulatory disorders of the legs--a double-blind study].
In a double blind study altogether 41 patients with obliterating arteriosclerosis at stage II after Fontaine have been treated for 26 weeks either with 3 X 100 mg Trapidil (Rocornal) daily or placebo. In the second half of the study under Trapidil in contrast to placebo a clinically relevant additional increase of the distance of the intermitent claudication was the result. On the other hand, the plethysmographically measured reserve of the arterial blood supply did not show any changes in the two groups. A specific influence of Trapidil on the lipoprotein metabolism is apparently not present, since there appeared favourable influence on the hyperlipoproteinaemia diagnosed in 37 out of 41 patients both under placebo and under Trapidil.
Voigt
H
H
Klinik für Innere Medizin, Bereichs Medizin der Karl-Marx-Universität Leipzig.
Reuter
W
W
Hofmann
B
B
Dobberkau
A
A
D000368:Aged; D001162:Arteriosclerosis Obliterans / Q000188:drug therapy*; D002784:Cholesterol / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007511:Ischemia / Q000188:drug therapy*; D007866:Leg / Q000098:blood supply*; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000627:therapeutic use*; D014192:Trapidil / Q000009:adverse effects / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D011743:Pyrimidines; D014280:Triglycerides; D002784:Cholesterol; D014192:Trapidil
Orale Trapidiltherapie bei arteriosklerotischen Durchblutungsstörungen der Beine im Stadium II nach Fontaine--eine Doppelblindstudie.